Foresite Capital raises $900M sixth fund for investing in life sciences companies

Venture fundraising has been a slog over the last few years, even for firms with a strong track record. That’s Foresite Capital’s experience. Despite having 47 IPOs, 28 M&As and 58 FDA-approved drugs under its belt, the 13-year-old multi-stage healthcare and life sciences firm took two years to raise its sixth fund. “Almost all of […]
© 2024 TechCrunch. All rights reserved. For personal use only.

Top Articles